The 36-month beta value for BBIO is also noteworthy at 1.06. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 5 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for BBIO is 148.37M, and at present, short sellers hold a 12.66% of that float. The average trading volume of BBIO on February 25, 2025 was 2.67M shares.
BBIO) stock’s latest price update
The stock price of BridgeBio Pharma Inc (NASDAQ: BBIO) has dropped by -8.28 compared to previous close of 36.25. Despite this, the company has seen a fall of -6.31% in its stock price over the last five trading days. globenewswire.com reported 2025-02-24 that – Long term debt management strategy will strengthen the balance sheet without increasing total liabilities – Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends debt maturity PALO ALTO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today that it intends to offer, subject to market conditions and other factors, $500 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).
BBIO’s Market Performance
BBIO’s stock has fallen by -6.31% in the past week, with a monthly drop of -11.55% and a quarterly rise of 44.31%. The volatility ratio for the week is 6.32% while the volatility levels for the last 30 days are 5.40% for BridgeBio Pharma Inc The simple moving average for the last 20 days is -2.39% for BBIO’s stock, with a simple moving average of 20.00% for the last 200 days.
Analysts’ Opinion of BBIO
Piper Sandler gave a rating of “Overweight” to BBIO, setting the target price at $46 in the report published on September 04th of the previous year.
BBIO Trading at 4.26% from the 50-Day Moving Average
After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.76% of loss for the given period.
Volatility was left at 5.40%, however, over the last 30 days, the volatility rate increased by 6.32%, as shares sank -7.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.47% upper at present.
During the last 5 trading sessions, BBIO fell by -4.70%, which changed the moving average for the period of 200-days by +21.71% in comparison to the 20-day moving average, which settled at $34.09. In addition, BridgeBio Pharma Inc saw 21.17% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BBIO starting from STEPHENSON BRIAN C, who sale 4,148 shares at the price of $36.16 back on Feb 19 ’25. After this action, STEPHENSON BRIAN C now owns 102,464 shares of BridgeBio Pharma Inc, valued at $149,973 using the latest closing price.
Kumar Neil, the Chief Executive Officer of BridgeBio Pharma Inc, sale 31,543 shares at $36.14 during a trade that took place back on Feb 19 ’25, which means that Kumar Neil is holding 211,718 shares at $1,140,024 based on the most recent closing price.
Stock Fundamentals for BBIO
Current profitability levels for the company are sitting at:
- -2.66 for the present operating margin
- 0.99 for the gross margin
The net margin for BridgeBio Pharma Inc stands at -2.41. The total capital return value is set at -0.67.
Currently, EBITDA for the company is -592.97 million with net debt to EBITDA at 1.59. When we switch over and look at the enterprise to sales, we see a ratio of 25.63. The receivables turnover for the company is 46.99for trailing twelve months and the total asset turnover is 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.67.
Conclusion
In summary, BridgeBio Pharma Inc (BBIO) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
